Category Archives: Pharma Launch
In the pharmaceutical sector, disease state awareness campaigns are one of the few ways to reach patients and physicians before a product is approved. In essence, they set the table for future marketing efforts at product launch and post-launch. While
Blockbuster Launch Evolution: Learning to See the Market in Different Wavelengths and Perspectives (Part 2)
One of the areas within the Pharmaceutical and related industries which has the main goal of seeing market opportunities is the Market Research function. Despite this, many organizations’ Market Research groups do not have 20/20 vision. Much like many animals
Take a look at the slide below and see if you can answer which of the 5 drugs had a peak sales year of $13.7 billion. The answer? – Lipitor While Lipitor sold a gigantic $13.7 billion in their peak sales year,
Can Sovaldi’s Launch Success Be Repeated? Examining How Gilead Sciences Utilized Marketing Mix To Rewrite Launch History
We all know this story: Ninety-five percent of drugs in the development pipeline fail to clear the safety and efficacy profiles, and companies then add that R&D cost of such failures to the price of the drug that does reach the
Companies frequently search for ways to gauge success and often come up with practical measures to decide whether a product is a boon or a bust. Executives often believe that by setting measurable goals that brand teams can create a
In today’s competitive & crowded marketplace, biopharmaceutical companies are investing more and more resources to develop and launch new products for cardiovascular therapeutic areas. Consequently, recent industry product launches have produced both noteworthy failures and successes. It is now, more
Challenge: How does an organization launch & grow multiple products for a common therapeutic area while keeping costs down & efficiently deploying Sales & Marketing resources? Launching and growing multiple products for a common therapeutic area is a challenging proposition.
The success of a pharmaceutical organization’s pipeline is often linked to the effectiveness of its new product commercialization function. Despite this, there is no consensus on what separates an effective early-stage commercialization group from an ineffective one. While the success
With the growth of patent expirations, the importance of planning groups in new pharma product ventures has grown. These new product launch groups are faced with the pressures of efficiently developing new products with both minimum risk and maximum value.
To maximize the value of a brand at every stage of its life, pharmaceutical companies are increasingly focused on lifecycle management (LCM). Considering the nature of the pharmaceutical industry, with expiring patents and thin pipelines, brand executives are consistently examining
In order to promote the benefits of new therapies and products, pharmaceutical organizations increasingly rely on brand websites. While this new technique may inform the stakeholders involved, it can be challenging to successfully launch a new product’s website globally. Along
The continually evolving product launch landscape can be enough to make or break a market entry. With many leading pharmaceutical organizations in the process of launching new products, many leaders are rethinking the factors that play the biggest role in the current
Link to this post!
Building Bridges to Key Audiences: Educating the Marketplace for Successful Diabetes Product Launches
Educating, informing, and preparing the marketplace for new products are all key factors in achieving the ultimate product success desired by organizations. Through the use of Physician, Payer and Patient education, as well as preparing publications and communication strategies, leaders